Prevalence of ARMD to Double by 2050 According to Recent Study

April 16, 2009

The prevalence of all forms af age-related macular degeneration (ARMD) is projected to almost double between 2010 and 2050 according to an analysis reported in the April edition of the Archives of Ophthalmology.  Using multivariant scenerios; however, the use of anti-oxidant vitamins and present therapies (such as anti-VEGF injections) will reduce the amount of vision loss by 35%.

The authors measured various types and stages of ARMD including early AMD, “wet” AMD and geographic atrophy (GA) against five different treatment scenarios.  In each case, while the prevalence of the disease increases,  the use of antioxidant supplements reduces the visual morbidity.

There are several limitations to this studay say the authors, including the fact that future predictions do not include advancements in treating the disease nor any long term data regarding anti-VEGF therapy.

The point is clear; however, the number of people suffering from this is going to rise dramatically.  Using this analysis, it seems we are pointed in the right direction.

Randall V. Wong, M.D.
Retinal Specialist




Jump down to form below to submit your own comments

One Response to “Prevalence of ARMD to Double by 2050 According to Recent Study”

  • Just a reminder, I have published two listings; one of current clinical trials for AMD, and the other of investigative therapies for both dry and wet AMD.

    Current Clinical Trials for AMD:

    Investigative Therapies for AMD:

    Irv Arons